NT-112 for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests NT-112, a personalized immune cell treatment, in patients with advanced cancers that have a specific genetic mutation. The treatment boosts the patient's immune cells to target and kill cancer cells. This highly personalized cancer therapy involves giving the patient immune cells that directly attack cancer.
Will I have to stop taking my current medications?
The trial requires that you stop any systemic therapy (treatment affecting the whole body) at least 2 weeks before joining. If you're on such medications, you may need to stop them before participating.
How is the treatment NT-112 different from other treatments for solid tumors?
What data supports the effectiveness of the drug NT-112 for solid tumors?
Are You a Good Fit for This Trial?
This trial is for adults over 18 with advanced solid tumors like lung, colorectal, pancreatic or endometrial cancer that can't be surgically removed and have worsened despite treatment. Participants must have a specific genetic feature (KRAS G12D mutation) and a certain immune system marker (HLA-C*08:02). They should be relatively well-functioning (ECOG status of 0-1).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive NT-112, an autologous T-cell therapy product, with dose escalation to determine safety and preliminary anti-tumor activity
Follow-up
Participants are monitored for safety, including dose-limiting toxicities and adverse events
Long-term follow-up
Participants are monitored for overall survival and long-term safety
What Are the Treatments Tested in This Trial?
Interventions
- NT-112
Find a Clinic Near You
Who Is Running the Clinical Trial?
Neogene Therapeutics, Inc.
Lead Sponsor
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology